• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

4.410 -0.320 (-6.77%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,474
Open 4.670
Bid (Size) 4.390 (400)
Ask (Size) 4.400 (300)
Prev. Close 4.730
Today's Range 4.385 - 4.695
52wk Range 4.109 - 16.45
Shares Outstanding 33,197,018
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
October 21, 2026
A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth 
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
October 14, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 73.2% below 52-week high
4.410
4.1152W Low 16.4552W High
1 Week 16.3% below 1-week high
4.271W Low 5.271W High

Entrada Therapeutics, Inc. - Common Stock (TRDA) traded between $4.11 and $16.45 over the past 52 weeks and last traded at $4.41, 73.2% below its 52-week high. Over the past week it ranged between $4.27 and $5.27.

Past 12 Months
-8.5%
-32.2%
-24.6%
-65.1%
-56.1%
-31.1%
1W -$0.41
1M -$2.09
3M -$1.44
6M -$8.22
YTD -$5.64
1Y -$1.99

TRDA was -31.1% over the past year, -65.1% over six months, -56.1% year to date, -8.5% in the last week.

12 Months vs Market
TRDA
-31.1%
DIA
+11.6%
SPY
+13.1%
QQQ
+15.4%
IWM
+11.9%

Over the past 12 months TRDA returned -31.1% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.55× 3-mo avg
Today 191,474 3-mo avg 348.3K
1W
393.3K
1M
370.0K
3M
348.3K
6M
403.4K
YTD
330.5K
1Y
312.0K

TRDA most recently traded 191,474 shares against a 3-month average daily volume of 348.3K.

More News

Read More
News headline image
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
October 14, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
September 10, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure ↗
May 07, 2026
Via Chartmill
News headline image
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
August 05, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
June 02, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
May 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile ↗
May 09, 2026
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
May 07, 2026
Via Chartmill
Top stock movements in today's session. ↗
May 07, 2026
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
May 07, 2026
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
May 07, 2026
Via Chartmill
News headline image
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 07, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 07, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 06, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?
Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?
Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?
The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market
What is the current price of Entrada Therapeutics, Inc. - Common Stock?
The current price of Entrada Therapeutics, Inc. - Common Stock is 4.410
When was Entrada Therapeutics, Inc. - Common Stock last traded?
The last trade of Entrada Therapeutics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?
The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 146.40M
How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?
Entrada Therapeutics, Inc. - Common Stock has 146M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap